AAAAAA

   
Results: 1-20 |
Results: 20
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
Authors: Foudraine, NA Jurriaans, S Weverling, GJ Burger, DM Hoetelmans, RMW Roos, MTL Maas, J Miedema, F Reiss, P Portegies, P de Wolf, F Lange, JMA
Citation: Na. Foudraine et al., Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial, ANTIVIR TH, 6(1), 2001, pp. 55-62
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1
Authors: van Praag, RME van Heeswijk, RPG Jurriaans, S Lange, JMA Hoetelmans, RMW Prins, JM
Citation: Rme. Van Praag et al., Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1, CLIN INF D, 33(8), 2001, pp. E91-E92
Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection
Authors: Enting, RH Prins, JM Jurriaans, S Brinkman, K Portegies, P Lange, JMA
Citation: Rh. Enting et al., Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection, CLIN INF D, 32(7), 2001, pp. 1095-1099
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+T cell depletion
Authors: Van Praag, RME Prins, JM Roos, MTL Schellekens, PTA Ten Berge, IJM Yong, SL Schuitemaker, H Eerenberg, AJM Jurriaans, S De Wolf, F Fox, CH Goudsmit, J Miedema, F Lange, JMA
Citation: Rme. Van Praag et al., OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+T cell depletion, J CLIN IMM, 21(3), 2001, pp. 218-226
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy
Authors: Reijers, MHE Weverling, GJ Jurriaans, S Roos, MTL Wit, FWNM Weigel, HM Ten Kate, RW Mulder, JW Richter, C Ter Hofstede, HJM Sprenger, H Hoetelmans, RMW Schuitemaker, H Lange, JMA
Citation: Mhe. Reijers et al., The ADAM study continued: maintenance therapy after 50 weeks of induction therapy, AIDS, 15(1), 2001, pp. 129-131
High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function
Authors: Kostense, S Ogg, GS Manting, EH Gillespie, G Joling, J Vandenberghe, K Veenhof, EZ van Baarle, D Jurriaans, S Klein, MR Miedema, F
Citation: S. Kostense et al., High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function, EUR J IMMUN, 31(3), 2001, pp. 677-686
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy
Authors: Gisolf, EH van Praag, RME Jurriaans, S Portegies, P Goudsmit, J Danner, SA Lange, JMA Prins, JM
Citation: Eh. Gisolf et al., Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy, J ACQ IMM D, 25(5), 2000, pp. 426-433
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations
Authors: Notermans, DW De Wolf, F Oudshoorn, P Cuijpers, HT Pirillo, M Tiller, FW McClernon, DR Prins, JM Lange, JMA Danner, SA Goudsmit, J Jurriaans, S
Citation: Dw. Notermans et al., Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations, AIDS RES H, 16(15), 2000, pp. 1507-1517
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir
Authors: van Praag, RME Weverling, GJ Portegies, P Jurriaans, S Zhou, XJ Turner-Foisy, ML Sommadossi, JP Burger, DM Lange, JMA Hoetelmans, RMW Prins, JM
Citation: Rme. Van Praag et al., Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14(9), 2000, pp. 1187-1194
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
Authors: Gisolf, EH Jurriaans, S Pelgrom, J van Wanzeele, F van der Ende, ME Brinkman, K Borst, MJ de Wolf, F Japour, AJ Danner, SA
Citation: Eh. Gisolf et al., The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine, AIDS, 14(4), 2000, pp. 405-413
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection
Authors: Putter, H Prins, JM Jurriaans, S Roos, M Ferguson, NM van Praag, R van der Hoek, L Schuitemaker, H Anderson, RM Goudsmit, J Lange, JMA de Wolf, F
Citation: H. Putter et al., Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection, AIDS, 14(18), 2000, pp. 2831-2839
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
Authors: den Brinker, M Wit, FWNM Wertheim-van Dillen, PME Jurriaans, S Weel, J van Leeuwen, R Pakker, NG Reiss, P Danner, SA Weverling, GJ Lange, JMA
Citation: M. Den Brinker et al., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14(18), 2000, pp. 2895-2902
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
Authors: Gisolf, EH Enting, RH Jurriaans, S de Wolf, F van der Ende, ME Hoetelmans, RMW Portegies, P Danner, SA
Citation: Eh. Gisolf et al., Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine, AIDS, 14(11), 2000, pp. 1583-1589
Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine
Authors: Enting, RH Foudraine, NA Lange, JMA Jurriaans, S van der Poll, T Weverling, GJ Portegies, P
Citation: Rh. Enting et al., Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine, J NEUROIMM, 102(2), 2000, pp. 216-221
Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers
Authors: Kassa, E de Wit, TFR Hailu, E Girma, M Messele, T Mariam, HG Yohannes, S Jurriaans, S Yeneneh, H Coutinho, RA Fontanet, AL
Citation: E. Kassa et al., Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers, AIDS, 13(3), 1999, pp. 381-389
Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
Authors: Prins, JM Jurriaans, S van Praag, RME Blaak, H van Rij, R Schellekens, PTA ten Berge, IJM Yong, SL Fox, CH Roos, MTL de Wolf, F Goudsmit, J Schuitemaker, H Lange, JMA
Citation: Jm. Prins et al., Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS, 13(17), 1999, pp. 2405-2410
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
Authors: de Jong, JJ Goudsmit, J Lukashov, VV Hillebrand, ME Baan, E Huismans, R Danner, SA ten Veen, JH de Wolf, F Jurriaans, S
Citation: Jj. De Jong et al., Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs, AIDS, 13(1), 1999, pp. 75-80
Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
Authors: Ogg, GS Kostense, S Klein, MR Jurriaans, S Hamann, D McMichael, AJ Miedema, F
Citation: Gs. Ogg et al., Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression, J VIROLOGY, 73(11), 1999, pp. 9153-9160
Outcome and predictors of failure of highly active antiretroviral therapy:One-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons
Authors: Wit, FWNM van Leeuwen, R Weverling, GJ Jurriaans, S Nauta, K Steingrover, R Schuijtemaker, J Eyssen, X Fortuin, D Weeda, M de Wolf, F Reiss, P Danner, SA Lange, JMA
Citation: Fwnm. Wit et al., Outcome and predictors of failure of highly active antiretroviral therapy:One-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons, J INFEC DIS, 179(4), 1999, pp. 790-798
Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers
Authors: Kassa, E de Wit, TFR Hailu, E Girma, M Messele, T Mariam, HG Yohannes, S Jurriaans, S Yeneneh, H Coutinho, RA Fontanet, AL
Citation: E. Kassa et al., Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers, ETHIOP MED, 37, 1999, pp. 67-75
Risultati: 1-20 |